Telix Refinances Convertible Bonds
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The new bonds will provide cost-effective financing and are non-dilutive until conversion occurs, with the initial conversion price set at a premium to the current share price. Concurrent with the offering, a delta placement of ordinary shares will be executed to facilitate hedging activities related to the convertible bonds.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallTelix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- Telix and Regeneron Announce Strategic Radiopharma Collaboration
- Regeneron and Telix Announce Strategic Radiopharma Collaboration
- Telix and Regeneron Announce Radiopharma Collaboration
- FDA Accepts NDA for TLX101-Px (Pixclara)
- Telix Strengthens Board with Additional Director Appointments
Later from Telix Pharmaceuticals
- Telix Investor Presentation April 2026
- Telix Successfully Prices Upsized US$600M Convertible Bonds
- Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds
- Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
- ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals